Question-and-Answer Session
Operator
Ladies and gentlemen, the question-and-answer session will be conducted electronically. (Operator Instructions)
Our first question will come from Ms. Alexandra Hauber with Bear Stearns. Please go ahead.
Alexandra Hauber - Bear Stearns
Yes, good afternoon. I have four questions please. David, could you speak a bit to the dynamics in the U.S. patent market. What do you need to do going forward to win a battle for improving market share again. Is it a question of access? Is it a question of convincing doctors not to prescribe generic simvastatin? Is it a question of the patients in the co-pay? And could you also just mention how would a label enhancement with the atherosclerosis label which we will learn next week would fit into that picture?
And second question, since we have different dynamics for Nexium outside the U.S. in the different regions, is there any chance you can give us a rough split of, the size of Western Europe versus the rest of the world?
And then the third question is, at the second quarter result David you were still confident that you can grow the business in the near-term in the next three years in line with the world market. In view of the definitely challenging environment on the PPI and stocking market, are you still confident you can do this?
And then fourth question is a very tiny technical question, in view of the considerable Seroquel XR launch talk, well investor sales through a [hockey stick] in the next few weeks which based on what you described, I wouldn't expect. Is there any risk you have to consider negative sales in the fourth quarter for the XR version?
David Brennan
Okay. Let me start with your question about the U.S. statin market and proposition, I mean clearly the market itself has been significantly impacted by the introduction of generic simvastatin, you see it in, as I said, the loss of share for Lipitor and the share gain for generic simvastatin. And then Vytorin and Crestor have essentially stayed relatively flat.
So our goal is to get back to growth. First thing, we look at is promotion or share a voice in the market is competitive with Lipitor, and just a little bit behind Vytorin, but they are the only three products that are being promoted. So, I think we have been stayed very competitive from a share of voice and sampling perspective, which are couple of the metrics that we can pick up from the market to see how that's doing. I think the messaging will change a bit depending on the outcome of the labeling discussion around the atheroma label.
- To read the full transcript on Seeking Alpha, click here »
